Sign In
Buy GSK
$51.46
-0.0700 (-0.136%)
At Close: Aug 05, 2026
DivHut Dividend Income Update: January 2024
07:30am, Friday, 16'th Feb 2024
DivHut Dividend Income Update: January 2024
GSK acquires respiratory firm Aiolos Bio for US$1.4 billion
05:01am, Thursday, 15'th Feb 2024
GSK PLC (LSE:GSK, NYSE:GSK) has announced the US$1.4 billion acquisition of respiratory biopharmaceuticals firm Aiolos Bio. FTSE 100-listed GSK said the takeover, which will se US$1 billion paid upfro
GSK plc: An Undervalued Vaccine Behemoth That Is Resuming Growth; Buy
02:45am, Thursday, 15'th Feb 2024
GSK plc is a multinational “big pharma” and long-time leader in the vaccine, HIV, and respiratory disease areas. Shingrix and RSV vaccine sales in 2023 exceeded expectations and appear to show no
GSK completes acquisition of Aiolos Bio for up to $1.4 bln
02:41am, Thursday, 15'th Feb 2024
GSK said on Thursday it had completed the acquisition of Aiolos Bio, a clinical-stage biopharmaceutical company focused on respiratory and inflammatory conditions.
Hedge fund snaps up stake in Love Island maker ITV
05:23am, Tuesday, 13'th Feb 2024
A hedge fund has bought a 5% stake in the U.K.'s largest commercial television broadcaster ITV, as the broadcaster struggles against a slump in the advertising market that has pummeled its share price
GSK: American investment bank goes positive on the stock for the first time in seven years. Here's why
04:22am, Tuesday, 13'th Feb 2024
The healthcare team at Citi has turned positive on GSK PLC (LSE:GSK, NYSE:GSK) for the first time in seven years. Pushing the investment bank's analysts over the precipice to 'buy' was the outlook for
Why GSK (GSK) is a Top Momentum Stock for the Long-Term
10:51am, Monday, 12'th Feb 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
GSK granted US fast track status for chronic hepatits B treatment
02:37am, Monday, 12'th Feb 2024
GSK has been granted US Fast Track designation for bepirovirsen, an investigational treatment for chronic hepatitis B (CHB). A request was made to US regulator the FDA by the UK pharma due to an un
GSK agrees another Zantac settlement in California
03:39am, Thursday, 01'st Feb 2024
GSK PLC (LSE:GSK, NYSE:GSK) has reached a confidential settlement regarding a lawsuit in California, which accused its discontinued heartburn medication, Zantac, of causing cancer, thus avoiding a tri
GSK confidentially settles another Zantac lawsuit in California
02:11am, Thursday, 01'st Feb 2024
GSK said on Thursday it agreed to confidentially settle one more lawsuit in California that alleged its discontinued heartburn drug Zantac caused cancer, the latest in a series of settlements to end c
GSK Lags Q4 Earnings, Tops Sales, Issues Upbeat '24 Guidance
01:16pm, Wednesday, 31'st Jan 2024
GSK's revenues benefit from strong growth across all segments, especially the Shingles and RSV vaccines. The company also issues fresh 2024 guidance for all its segments.
GSK posts blowout RSV vaccine sales, raises outlook as shots give big pharma a boost
09:47am, Wednesday, 31'st Jan 2024
The RSV shot, called Abrysvo, booked £1.2 billion, or $1.5 billion, in sales after only being on the market for roughly half a year.
GSK (GSK) Misses Q4 Earnings Estimates
08:06am, Wednesday, 31'st Jan 2024
GSK (GSK) came out with quarterly earnings of $0.72 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.64 per share a year ago.
GSK lifts long-term outlook following launch of blockbuster vaccine in 2023
07:08am, Wednesday, 31'st Jan 2024
GSK on Wednesday lifted its long-term outlook for 2026-2031 as it predicted new drug and vaccine launches will see its annual sales hit £38 billion by the start of the next decade following the block
GSK raises sales outlook to 2031 ahead of 12 major product launches
02:35am, Wednesday, 31'st Jan 2024
GSK PLC (LSE:GSK, NYSE:GSK) on Wednesday increased its outlook for sales out to 2031 driven by a raft of major product launches from 2025. Chief Executive Emma Walmsley said: “We are now planning fo
